Health

  • August 10, 2026

    HHS Denies Existence Of $150M Deal With Texas Firm To Rep Migrant Kids

    The U.S. Department of Health and Human Services said Monday that a small law firm in Houston had not yet been tapped for a sole-source grant worth up to $150 million to provide legal services to unaccompanied migrant children in government custody.

  • August 10, 2026

    Trump Revives Push To Reduce Kids' Vaccine Schedule

    Responding to a legal setback, President Donald Trump signed an executive order Monday recommending fewer vaccines for most children and calling on parents and doctors to space out the vaccines they do give.

  • August 10, 2026

    9th Circ. Backs FDA's Denial Of Fruit-, Candy-Flavored Vapes

    The Ninth Circuit on Monday affirmed the U.S. Food and Drug Administration's denial of Drip More LLC's applications to sell candy- and fruit-flavored vapes, saying the company didn't show those flavors provide an additional benefit to adult smokers that justifies the added risks that young people will use the products.

  • August 10, 2026

    ModivCare Execs Must Face Suit Over Cash Flow Woes

    A Colorado federal judge has declined to toss a shareholder class action against current and former executives of patient transportation company ModivCare Inc. over their alleged failure to disclose the negative impact of certain contract renegotiations, finding that the investors pled actionable misstatements.

  • August 10, 2026

    Clinics' Suit Over Fund Use Ballot Measure Gets Tossed

    A California federal judge tossed a suit that federally designated community health clinics filed to block the placement of an expenditure transparency reporting initiative on the November ballot, saying the clinics' claims aren't ripe for court review.

  • August 10, 2026

    AbbVie, Novartis Seek To Block Ill. 340B Drug Discount Law

    AbbVie Inc. and Novartis Pharmaceuticals are urging an Illinois federal court to block a state law that took effect Friday barring pharmaceutical manufacturers from trying to impose restrictions on 340B contract pharmacy arrangements, arguing in a pair of suits that the law is unconstitutional.

  • August 10, 2026

    Welch Allyn, IRhythm Reach Deal To End Patent Dispute

    Welch Allyn Inc. has entered a deal to bring a close to a lawsuit in Delaware federal court accusing iRhythm Technologies Inc. of infringing a series of heart monitor patents after iRhythm had its attempts to challenge some of those patents shot down.

  • August 10, 2026

    Tax Man Who Shaved Insurance Crook's Income Gets 2 Years

    A Manhattan federal judge has sentenced a preparer of fraudulent tax returns to two years in prison after prosecutors said his cooperation against a client who operated a bribery-fueled insurance scam was marred by confusing proffers and altered records.

  • August 10, 2026

    H.I.G. Can't Block Calif. Suit Over $17.5M Health Deal

    The Delaware Chancery Court on Monday refused to block two former behavioral health facility owners from pursuing a California securities fraud suit against private equity firm H.I.G. Capital LLC and its affiliates, finding the companies had not shown the dispute must be litigated in Delaware.

  • August 10, 2026

    Arkansas Medical System Escapes Target-Date 401(k) Suit

    An Arkansas federal judge on Monday dismissed a proposed class action alleging Arkansas medical system Washington Regional mismanaged the system's employee 401(k) plan, holding that allegations of underperforming investment funds weren't backed up with enough comparisons to better-performing ones to state a claim for violating federal benefits law.

  • August 10, 2026

    11th Circ. Affirms Ga. University System's Win In Bias Suit

    The Eleventh Circuit on Monday upheld a win for the University System of Georgia in a disability discrimination case brought by a former respiratory therapy student who alleged he was improperly found to be endangering patients' safety and given a failing grade as punishment.

  • August 10, 2026

    Alto Neuroscience Escapes Investor Drug Trial Suit, For Now

    Alto Neuroscience has escaped a shareholder suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, with a California federal judge ruling that the suit's "vague and conclusory" pleadings should be remedied.

  • August 10, 2026

    8th Circ. Nixes Native American Worker's Race Bias Suit

    The Eighth Circuit on Monday upheld a clinical research institute's defeat of a lawsuit from a former manager who said she was laid off because she's Native American, siding with the institute's assertion that she was let go for budgetary reasons because her position was funded with internal money.

  • August 10, 2026

    Judge Trims BCBS Privacy Suit Over Public Site Data

    Blue Cross Blue Shield Association beat most claims in a proposed privacy class action Friday when an Illinois federal judge ruled that federal employees' searches for doctors, symptoms and medical conditions on its public website did not amount to protected health information.

  • August 10, 2026

    Mass. Court Says Insurer Must Defend Doctor In Stalking Case

    Massachusetts' highest court has ruled that an insurance company must defend a doctor in disciplinary proceedings for allegedly stalking and harassing a patient to whom he prescribed an addictive medication for several years.

  • August 10, 2026

    Northwestern To Pay $4M In COVID-Era Tuition Refunds

    Northwestern University is set to pay $4 million to settle students' pursuit of refunds after the COVID-19 pandemic forced class instruction online, which the students alleged violated their agreement with the university.

  • August 10, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving merger settlements, contract claims, controlling stockholders, music rights, prejudgment interest, absentee voting and stockholder standing.

  • August 10, 2026

    Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push

    Dublin-based Jazz Pharmaceuticals PLC said Monday it will pay up to $1.32 billion for privately held Actio Biosciences, with Hogan Lovells Cadwalader advising Jazz and Cooley LLP guiding Actio. 

  • August 10, 2026

    3 Firms Guide Teledyne's $1.1B Varex Imaging Deal

    Teledyne Technologies Inc. said Monday it has agreed to purchase Varex Imaging Corp. in a deal valued at about $1.1 billion, with Latham & Watkins LLP and McGuireWoods LLP advising Teledyne and Orrick Herrington & Sutcliffe LLP representing Varex.

  • August 07, 2026

    Carradine Family Says UCLA Ignored Suicide Watch Rules

    The family of Robert Carradine sued the Regents of the University of California Friday in Los Angeles court, alleging the actor's death after a suicide attempt while in a UCLA facility came because staff ignored several key policies about patients on suicide watch.

  • August 07, 2026

    Taco Bell, Taylor Farms Sued Over Tainted Lettuce

    A Florida consumer hit Taco Bell and Taylor Farms with a proposed class action Thursday over the ongoing cyclospora outbreak caused by contaminated lettuce, which so far has affected thousands of people in multiple states and been linked to two deaths.

  • August 07, 2026

    VA To Test Psilocybin For Veterans With Severe Depression

    Former military service members in five U.S. cities will have an opportunity to treat their depression with psilocybin through a clinical trial being run by the U.S. Department of Veterans Affairs, according to an agency announcement.

  • August 07, 2026

    Texas Docs Can't Exit Patient's Hernia Surgery Death Suit

    A Texas appellate court has refused to toss a suit accusing two doctors of causing a hernia surgery patient's death, finding that the plaintiff submitted an expert report that met the "low threshold" required under the state's medical malpractice statute.

  • August 07, 2026

    Fired Doc, Fla. Hospital Strike Deal In Age Bias Suit

    A Florida doctor has settled an age discrimination suit against a hospital that he claimed abruptly pulled a contract renewal and replaced him with a much younger doctor.

  • August 07, 2026

    Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK

    A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.

Expert Analysis

  • New Timeline For Benefits Cases May Increase FCA Litigation

    Author Photo

    Recent reforms designed to speed enforcers’ intervention decisions in False Claims Act suits involving state-administered benefits will likely encourage more qui tam relators to litigate cases without the government’s imprimatur, and increase defendants’ discovery burdens, defense costs and business disruptions, say attorneys at Morgan Lewis.

  • Why Highly Specialized Experts May Risk Exclusion At Trial

    Author Photo

    Expert witnesses with highly specific areas of focus may be vulnerable to exclusion in court, making it important for attorneys to check how potential witnesses' qualifications can be bolstered by their publications and other professional activities, say Evan Weisberg and Christopher Cunio at Hunton, and Kevin Cahill at FTI Consulting.

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

  • Opinion

    FTC's Clinical Trial Requirement Threatens Food Claim Rules

    Author Photo

    The Federal Trade Commission's general requirement for randomized controlled trials for most health-benefit claims, recently embraced by the National Advertising Review Board, lacks legal basis and endangers the existing statutory framework Congress created for marketing food and dietary supplements versus drugs, say attorneys at Keller & Heckman.

  • Drawing A Line Between Settlement Pressure And Extortion

    Author Photo

    U.S. v. Luo, pending in the U.S. District Court for the Southern District of New York, may force courts to address anew when settlement negotiations become criminal extortion, particularly in the age of easily fabricated digital evidence, says attorney Denis Kiely.

  • Risk Reduction Lessons For PE Firms From PowerSchool Suit

    Author Photo

    A California federal court's recent orders allowing claims against Bain Capital to proceed based on a data breach at its subsidiary PowerSchool indicate that private equity firms need to strategically approach acquisition activities to avoid cybersecurity risks, say attorneys at Womble Bond.

  • FTC Focus: Calibrating Biden-Era Issues In 2026's 1st Half

    Author Photo

    In the first half of 2026, Federal Trade Commission actions have redefined which of the previous administration's theories it views as legally sustainable, institutionally worthwhile and consistent with a more restrained conception, including a pivot from rulemaking to case-specific noncompete enforcement this spring, say attorneys at Proskauer.

  • Series

    Founding An Autism Academy Made Me A Better Lawyer

    Author Photo

    Starting a nonprofit autism school with no building, no funding model and no guarantee that families would trust us taught me the importance of mission, patience and purpose — lessons that sharpened my practice and showed how meaningful work outside the office can make lawyers better, says Phillip Russell at Ogletree Deakins.

  • HHS Enforcement Restructuring Signals Compliance Risks

    Author Photo

    The U.S. Department of Health and Human Services' recent restructuring of its Office for Civil Rights suggests that, while Health Insurance Portability and Accountability Act enforcement remains central, its priorities have expanded to encompass civil rights, conscience and religious freedom, and data and cybersecurity issues, say attorneys at King & Spalding.

  • Using NY Lawsuit Loan Law, Ruling Against Shady Injury Suits

    Author Photo

    The combination of a New York state appellate ruling that exposes litigation lenders in potentially fraudulent personal injury cases to discovery and a new law limiting predatory loans to plaintiffs provides defense counsel a powerful new toolkit for confronting suspicious claims, say attorneys at Stradley Ronon.

  • Opinion

    Rule Of Law Requires Gov't Engagement With Bar, Not Retreat

    Author Photo

    A federal agency's absence from national and local bar conferences, most recently illustrated by the U.S. Department of Justice's withdrawal from a New York City Bar Association white collar conference, disserves the bar, the government lawyers themselves and, ultimately, the administration of justice, says Muhammad Faridi at Linklaters.

  • AG Watch: Oregon's Strategic Civil Enforcement Approach

    Author Photo

    Oregon Attorney General Dan Rayfield’s recent antitrust litigation activity and proposed staffing increase are the latest in a series of structural and policy changes that signal that the state Department of Justice is taking a more aggressive approach to civil enforcement, says Keturah Taylor at Cozen O'Connor.

  • Fed. Circ. Clarifies Standard For Contesting CICA Overrides

    Author Photo

    The Federal Circuit's recent holding in Life Science Logistics strengthens the hand of protesters facing an override of the Competition in Contracting Act stay, and a Court of Federal Claims decision the same day demonstrates that how a protester frames its requested relief remains critically important, says Richard Arnholt at Bass Berry.

  • The Paradoxical Duty To Adopt AI When You Can't Bill For It

    Author Photo

    Both billing for hours saved using artificial intelligence and preserving billable time by not adopting AI may violate rules of professional conduct, but until bar associations' ethics rules catch up to this emerging economic dilemma, firms must decide how to adjust fee structures themselves, says Ines Lassalle at Peyrot & Associates.

  • A Decade Later, Escobar Is Still Shaping FCA Cases

    Author Photo

    The U.S. Supreme Court's decision 10 years ago in Universal Health Services v. U.S. ex rel. Escobar changed the way in which lower courts evaluate False Claims Act cases — and the ruling remains vital in nearly every FCA case filed today, say attorneys at Bradley Arant.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.